TriangleNCT00628251 · OUTCOME
Overall Duration of Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
What was measured
The duration of response was defined as time (months) from initial assessment of PR/CR until earliest date of objective progression or death. (Values may be underestimated as some patients had not progressed at final analysis so true duration is likely to be greater than that in database.)
Analysis population: Duration of response is analysed for patients experiencing a response.
Groups in this outcome
Olaparib 200 mg bd
Olaparib (AZD2281) 200 mg oral capsules twice daily
Olaparib 400 mg bd
Olaparib (AZD2281) 400 mg oral capsules twice daily
Olaparib 200 mg bd + Olaparib 400 mg bd,
Olaparib (AZD2281) 200 or 400 mg oral capsules twice daily
Liposomal Doxorubicin
Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks
| Group | Source count |
|---|---|
| Olaparib 200 mg bd | 8 |
| Olaparib 400 mg bd | 10 |
| Olaparib 200 mg bd + Olaparib 400 mg bd, | 18 |
| Liposomal Doxorubicin | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Olaparib 200 mg bd | 5.95 | Not reported | 3.71 | NA | The upper limit for the 95% CI was not reached. |
| Olaparib 400 mg bd | 6.80 | Not reported | 5.52 | 7.39 | Not reported |
| Olaparib 200 mg bd + Olaparib 400 mg bd, | 6.24 | Not reported | 5.52 | 7.39 | Not reported |
| Liposomal Doxorubicin | 5.49 | Not reported | 4.67 | 9.13 | Not reported |
Complete source fields
- classes
- categories
- measurements
- comment
- The upper limit for the 95% CI was not reached.
- group Id
- OG000
- lower Limit
- 3.71
- upper Limit
- NA
- value
- 5.95
- group Id
- OG001
- lower Limit
- 5.52
- upper Limit
- 7.39
- value
- 6.80
- group Id
- OG002
- lower Limit
- 5.52
- upper Limit
- 7.39
- value
- 6.24
- group Id
- OG003
- lower Limit
- 4.67
- upper Limit
- 9.13
- value
- 5.49
- denoms
- counts
- group Id
- OG000
- value
- 8
- group Id
- OG001
- value
- 10
- group Id
- OG002
- value
- 18
- group Id
- OG003
- value
- 6
- units
- Participants
- description
- The duration of response was defined as time (months) from initial assessment of PR/CR until earliest date of objective progression or death. (Values may be underestimated as some patients had not progressed at final analysis so true duration is likely to be greater than that in database.)
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Olaparib (AZD2281) 200 mg oral capsules twice daily
- id
- OG000
- title
- Olaparib 200 mg bd
- description
- Olaparib (AZD2281) 400 mg oral capsules twice daily
- id
- OG001
- title
- Olaparib 400 mg bd
- description
- Olaparib (AZD2281) 200 or 400 mg oral capsules twice daily
- id
- OG002
- title
- Olaparib 200 mg bd + Olaparib 400 mg bd,
- description
- Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks
- id
- OG003
- title
- Liposomal Doxorubicin
- param Type
- MEDIAN
- population Description
- Duration of response is analysed for patients experiencing a response.
- reporting Status
- POSTED
- time Frame
- At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
- title
- Overall Duration of Response
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice